Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression

Journal of Clinical Psychiatry

Volumn 72, Issue 7, 2011, Pages 962-969

  Portella, Maria J ^a,e   De Diego Adeliño, Javier ^a,e   Ballesteros, Javier ^a,b,e   Puigdemont, Dolors ^a,e   Oller, Sílvia ^a,e   Santos, Borja ^a,b,e   Álvarez, Enric ^a,e   Artigas, Francesc ^c,d,e   Pérez, Víctor ^a,e  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d CSIC   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PINDOLOL; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SURVIVAL TIME; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PINDOLOL; PSYCHOMETRICS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960706921     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05827blu     Document Type: Article

References (36)

1. Judd LL. Mood disorders in the general population represent an important and worldwide public health problem. Int Clin Psychopharmacol. 1995;10(suppl 4):5-10. doi:10.1097/04850-1951204-02 PubMed (Pubitemid 26058315)
2. Bech P, Cialdella P, Haugh MC, et al. Meta-analysis of randomised controlled trials of fluoxetine v placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry. 2000;176(5):421-428. doi:10.192/bjp.176.5.421 PubMed (Pubitemid 30249617)
3. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108. doi:10.1016/S0165-0327(98) 0138-4 PubMed (Pubitemid 28551779)
4. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157(9):1501-1504. doi:10.176/api.ajp.157.9.1501 PubMed
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.176/api.ajp.163.1.1905 PubMed (Pubitemid 44807782)
6. Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry. 2001;62(suppl 4):17-23, discussion 37-40. PubMed
7. Artigas F, Pérez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994;51(3):248-251. PubMed
8. Pérez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349(9065):1594-1597. doi:10.1016/S0140- 6736(96)0807-5 PubMed (Pubitemid 27229140)
9. Bordet R, Thomas P, Dupuis B; Réseau de Recherche et d'Expérimentation Psychopharmacologique. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry. 1998;155(10):1346-1351. PubMed
10. Geretsegger C, Bitterlich W, Stelzig R, et al. Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. Eur Neuropsychopharmacol. 2008;18(2):141-146. doi:10.1016/j. euroneuro.207.09.02 PubMed (Pubitemid 350296848)
11. Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord. 2004;79(1-3):137-147. doi:10.1016/S0165-0327(02)0404-4 PubMed (Pubitemid 38340537)
12. Whale R, Terao T, Cowen P, et al. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review [published online ahead of print October 2, 2008]. J Psychopharmacol. 2010;24(4):513-520. doi:10.17/0269810809714 PubMed
13. Goodnick PJ. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacol Bull. 1991;27(4):503-512. PubMed
14. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296. PubMed
15. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.doi:10.192/bjp.134.4. 382 PubMed (Pubitemid 9136500)
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
17. Collet D. Modelling Survival Data in Medical Research. London, England: Chapman & Hall; 1994.
18. Hilbe JM. Negative Binomial Regression. Cambridge, England: Cambridge University Press; 2007.
19. Jahn-Eimermacher A. Comparison of the Andersen-Gill model with poisson and negative binomial regression on recurrent event data. Comput Stat Data Anal. 2008;52(11):4989-4997. doi:10.1016/j.csda.208.04.09
20. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. doi:10.136/bmj.327.7414.57 PubMed (Pubitemid 37088507)
21. Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol. 1997;17(6):446-450. doi:10.1097/04714-197120-02 PubMed
22. Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol. 1997;12(2):81-89. PubMed
23. Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 1997;154(1):37-43. PubMed
24. Zanardi R, Franchini L, Gasperini M, et al. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol. 1998;18(6):441-446. doi:10.1097/04714-198120-04 PubMed (Pubitemid 28555326)
25. Berman RM, Anand A, Cappiello A, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry. 1999;45(9):1170-1177. doi:10.1016/S06-323(98)0383-7 PubMed (Pubitemid 29236558)
26. Zanardi R, Serretti A, Rossini D, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry. 2001;50(5):323-330. doi:10.1016/S06-323(01)018-0 PubMed (Pubitemid 32816944)
27. Rabiner EA, Bhagwagar Z, Gunn RN, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry. 2001;158(12):2080-2082. doi:10.176/api.ajp.158.12.2080 PubMed (Pubitemid 33104122)
28. 1A autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression? Neuropsychopharmacology. 2004;29(9):1688-1698. doi:10.1038/sj.np.130472 PubMed
29. Portella MJ, de Diego-Adeliño J, Puigdemont D, et al. Pindolol augmentation enhances response outcomes in first depressive episodes. Eur Neuropsychopharmacol. 2009;19(7):516-519. doi:10.1016/j.euroneuro.209.04.04 PubMed
30. Segrave R, Nathan PJ. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum Psychopharmacol. 2005;20(3):163-174. doi:10.102/hup.672 PubMed (Pubitemid 40561850)
31. Reed C, Monz BU, Perahia DG, et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009;113(3):296-302. doi:10.1016/j.jad.208.05.021 PubMed
32. Gilmer WS, Gollan JK, Wisniewski SR, et al. Does the duration of index episode affect the treatment outcome of major depressive disorder? a STAR*D report. J Clin Psychiatry. 2008;69(8):1246-1256. doi:10.408/JCP.v69n0807 PubMed
33. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516-1518. doi:10.176/api.ajp.160.8. 1516 PubMed (Pubitemid 41070930)
34. Colla M, Kronenberg G, Deuschle M, et al. Hippocampal volume reduction and HPA-system activity in major depression. J Psychiatr Res. 2007;41(7):553-560. doi:10.1016/j.jpsychires.206.06.01 PubMed (Pubitemid 46350730)
35. Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008;69(6):946-958. doi:10.408/JCP. v69n0610 PubMed (Pubitemid 351944948)
36. Tome MB, Isaac MT. One year real world prospective follow-up study of a major depressive episode of patients treated with paroxetine and pindolol or paroxetine for 6 weeks. Int Clin Psychopharmacol. 1998;13(4):169-174. doi:10.1097/04850-198070-03 PubMed (Pubitemid 28372340)